Healthcare - Biotechnology - NASDAQ - GB
$ 11.2
-3.78 %
$ 8.15 B
Market Cap
1.95
P/E
CASH FLOW STATEMENT
-765 M
OPERATING CASH FLOW
5.2 B
INVESTING CASH FLOW
419 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Roivant Sciences Ltd.
| Net Income | 4.23 B |
| Depreciation & Amortization | 22 M |
| Capital Expenditures | -1.38 M |
| Stock-Based Compensation | 200 M |
| Change in Working Capital | 19 M |
| Others | -5.24 B |
| Free Cash Flow | -767 M |
Cash Flow
Millions
| Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | 4 231.2 | (1 115.5) | (924.1) | (900.2) | (519.4) |
| Depreciation & Amortization | 22.0 | 18.9 | 5.9 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 199.6 | 217.8 | 565.0 | 85.0 | 0 |
| Other Operating Activities | (5 237.2) | 29.1 | (340.2) | 191.2 | (257.7) |
| Change in Working Capital | 19.0 | 6.3 | 15.7 | 71.9 | 15.3 |
| Cash From Operations | (765.3) | (843.4) | (677.7) | (552.1) | (761.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (1.4) | (12.7) | (17.4) | (5.8) | (4.9) |
| Other Items | 5 205.0 | (31.6) | 320.7 | (25.9) | 1 699.7 |
| Cash From Investing Activities | 5 203.6 | (44.3) | 303.3 | (31.7) | 1 694.8 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (1 188.5) |
| Total Debt Repaid | (30.7) | 129.8 | 14.8 | 0 | (32.1) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.5 | (10.0) | 292.0 | 0.5 | 83.5 |
| Cash From Financing Activities | 419.4 | 499.5 | 306.8 | 456.3 | 217.2 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 4 858.3 | (381.9) | (67.6) | (127.6) | 0 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (766.6) | (856.1) | (695.2) | (557.9) | (766.7) |